Biocon And Viatris Scoop EU Insulin Aspart Approval

Analyst Expects Biosimilar Penetration To Be ‘Slow And Minimal’

 
• By Dean Rudge

Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.

Europe_Map_Connection
Kixelle’s approval comes soon after Biocon announced the abrupt exit of Biocon Biologics’ CEO Christiane Hamacher • Source: Shutterstock

More from Products

More from Generics Bulletin